On August 18, 08.00 (CEST), the interim report January-June 2021 will be published and in connection with this, an earnings call will be arranged at 14:00 (CEST) the same day. The earnings call will be available afterwards on the company’s website.
Since the company is currently undergoing a name change from CELLINK to BICO, presentation material will be available at both www.cellink.com and www.bico.com. The presentation will be held in English.
Date: Wednesday, August 18, 2021. 14:00 (CEST)
For audio: +46 8 502 439 36 Conference-ID: 451 928 581#
For video: Video link to the presentation
Speakers: Erik Gatenholm, CEO and Gusten Danielsson, CFO
Please note for the Q&A session you have two options: a) if you participate via audio, you can ask your questions directly to the speakers b) if you participate via video, you can only ask questions via the chat function.
For further information, please contact:
Isabelle Ljunggren, Head of Communications
Phone: +46 70 830 08 90
The information was submitted for publication, through the agency of the contact person set out above on August 12, at 8am (CEST).
Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 2,000 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,700 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com